Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04666454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 14 to 16v6
  2. Phase: Phase 2 to Phase 4v5 Show 6 more changesShow less
    • Primary completion date: Jul 2024 to Dec 2028
    • Study sites: 4 to 14
    • Study completion date: Dec 2024 to Dec 2028
    • Eligibility criteria expanded, about 60 words
    • Collaborator revised
    • Study title expanded, about 1 word
  3. Re-verified, no change to tracked fieldsv4
  4. Study sites: 1 to 4
    • Secondary endpoints: 12 to 13
    v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary endpoints: 6 to 3
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2020 to Dec 14, 2020
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: 11 to 12
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients registered in SWEDEHEART will be included.
Trial Details
NCT Number NCT04666454
Lead Sponsor Vastra Gotaland Region
Collaborators: Göteborg University
Conditions
(from sponsor)		 Takotsubo Syndrome
Related terms Takotsubo Cardiomyopathy
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov